

FOR IMMEDIATE RELEASE

MedMira Announces Revocation of Cease Trade Order

Halifax, Nova Scotia, September 6, 2018 – MedMira Inc. (MedMira) (TSXV: MIR), announced that the Nova Scotia Securities Commission has revoked the Cease Trade Order, which was issued on August 31, 2018 due to late filing of documents related to the resignation of the Company's auditor, Deloitte LLP. The auditor issued notification of resignation when terms of engagement could not be established with MedMira. There were no reservations in Deloitte's reports on any of the Company's audited financial statements and no reportable events between MedMira and the auditor.

In accordance with National Instrument 51-102, the notice of change of auditor, together with the required letter from Deloitte LLP, have been reviewed by the audit committee and the board of directors and have been filed on SEDAR. The Company is now fully current on its regulatory disclosure filings. The Nova Scotia Securities Commission has issued a Revocation Order to the Cease Trade Order.

Trading through the TSX Venture Exchange remains halted pending the completion of the Company's reinstatement review.

About MedMira

MedMira is the developer and owner of Rapid Vertical Flow (RVF) Technology™. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal, Multiplo and Miriad™ brands in global markets. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada and the Company has a sales and customer service office located in the United States. For more information visit medmira.com. Follow us on [Twitter](#) and [LinkedIn](#).

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding the expected reinstatement of trading in the securities of the Company. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, the exercise of discretion by the TSX Venture Exchange with respect to the trading in the securities of the Company.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

MedMira Contacts:

Markus Meile, CFO

Tel: 902-450-1588

Email: m.meile@medmira.com

Andrea Young, Corporate Communications

Tel: 902-450-1588

Email: ayoung@medmira.com